دورية أكاديمية
Characterization of a miRNA Signature with Enhanced Diagnostic and Prognostic Power for Patients with Bladder Carcinoma.
| العنوان: | Characterization of a miRNA Signature with Enhanced Diagnostic and Prognostic Power for Patients with Bladder Carcinoma. |
|---|---|
| المؤلفون: | Samara M; Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41335 Larissa, Greece., Vlachostergios PJ; Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY 10065, USA., Thodou E; Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41335 Larissa, Greece., Zachos I; Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, University Hospital of Larissa, 41335 Larissa, Greece., Mitrakas L; Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, University Hospital of Larissa, 41335 Larissa, Greece., Evmorfopoulos K; Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, University Hospital of Larissa, 41335 Larissa, Greece., Tzortzis V; Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, University Hospital of Larissa, 41335 Larissa, Greece., Giakountis A; Department of Biochemistry and Biotechnology, University of Thessaly, 41335 Larissa, Greece. |
| المصدر: | International journal of molecular sciences [Int J Mol Sci] 2023 Nov 13; Vol. 24 (22). Date of Electronic Publication: 2023 Nov 13. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI, [2000- |
| مواضيع طبية MeSH: | MicroRNAs*/genetics , MicroRNAs*/metabolism , Urinary Bladder Neoplasms*/diagnosis , Urinary Bladder Neoplasms*/genetics, Humans ; Urinary Bladder/pathology ; Prognosis ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic |
| مستخلص: | Bladder carcinoma is globally among the most prevalent cancers and is associated with a high mortality rate at advanced stages. Its detection relies on invasive diagnostic methods that are unpleasant for the patient. Non-invasive molecular biomarkers, such as miRNAs, could serve as alternatives for early detection and prognosis of this malignancy. We designed a computational approach that combines transcriptome profiling, survival analyses, and calculation of diagnostic power in order to isolate miRNA signatures with high diagnostic and prognostic utility. Our analysis of TCGA-BLCA data from 429 patients yielded one miRNA signature, consisting of five upregulated and three downregulated miRNAs with cumulative diagnostic power that outperforms current diagnostic methods. The same miRNAs have a strong prognostic significance since their expression is associated with the overall survival of bladder cancer patients. We evaluated the expression of this signature in 19 solid cancer types, supporting its unique diagnostic utility for bladder carcinoma. We provide computational evidence regarding the functional implications of this miRNA signature in cell cycle regulation, demonstrating its abundance in body fluids, including peripheral blood and urine. Our study characterized a novel miRNA signature with the potential to serve as a non-invasive method for bladder cancer diagnosis and prognosis. |
| References: | Diagnostics (Basel). 2023 Aug 08;13(16):. (PMID: 37627884) Biomed Eng Online. 2021 Feb 16;20(1):21. (PMID: 33593374) Nucleic Acids Res. 2020 Jul 2;48(W1):W244-W251. (PMID: 32484539) Eur Urol. 2006 Dec;50(6):1254-60; discussion 1261-2. (PMID: 16831511) APMIS. 2019 Aug;127(8):545-553. (PMID: 31231851) Transl Androl Urol. 2021 Nov;10(11):4262-4274. (PMID: 34984191) J Urol. 2007 Apr;177(4):1277-82; discussion 1282. (PMID: 17382711) Cell Cycle. 2012 Dec 1;11(23):4352-65. (PMID: 23111389) Int J Mol Sci. 2020 Aug 14;21(16):. (PMID: 32823863) Urol Oncol. 2016 Oct;34(10):452-9. (PMID: 27381893) Urol Oncol. 2018 Dec;36(12):531.e1-531.e8. (PMID: 30322728) Oncogenesis. 2020 May 4;9(5):43. (PMID: 32366853) Eur Respir J. 2013 Mar;41(3):695-705. (PMID: 22790917) Sci Rep. 2020 Feb 21;10(1):3178. (PMID: 32081976) Cells. 2021 Nov 30;10(12):. (PMID: 34943882) Nucleic Acids Res. 2012 May;40(10):4288-97. (PMID: 22287627) Eur Urol Oncol. 2018 Sep;1(4):307-313. (PMID: 31100252) Front Microbiol. 2020 Jun 03;11:1197. (PMID: 32582115) Cancer Discov. 2020 Nov;10(11):1635-1644. (PMID: 33037026) Nucleic Acids Res. 2016 May 5;44(8):3865-77. (PMID: 26921406) J Am Soc Cytopathol. 2021 Jan-Feb;10(1):79-87. (PMID: 33160893) Eur Urol. 2005 Dec;48(6):951-6; discussion 956. (PMID: 16257108) Adv Exp Med Biol. 2014;772:205-27. (PMID: 24272361) Oncol Lett. 2017 Jan;13(1):435-440. (PMID: 28123579) J Cancer. 2019 Jul 8;10(17):4038-4044. (PMID: 31417648) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) BJU Int. 2012 Jul;110(1):84-94. (PMID: 22122739) Transl Androl Urol. 2023 Feb 28;12(2):286-299. (PMID: 36915886) Biomedicines. 2022 Oct 31;10(11):. (PMID: 36359288) Oncol Lett. 2020 Jan;19(1):606-614. (PMID: 31897176) Science. 2008 Mar 28;319(5871):1785-6. (PMID: 18369135) Clin Chem. 1999 Apr;45(4):472-7. (PMID: 10102906) Bioinformatics. 2016 Sep 15;32(18):2847-9. (PMID: 27207943) F1000Res. 2016 Jun 20;5:1438. (PMID: 27508061) Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308) J Pers Med. 2021 Mar 23;11(3):. (PMID: 33806972) Oncol Rep. 2017 Aug;38(2):1156-1162. (PMID: 28627699) Biomed Pharmacother. 2020 Nov;131:110703. (PMID: 32890965) Cancers (Basel). 2019 Jun 27;11(7):. (PMID: 31252695) Acta Cytol. 2011;55(2):113-9. (PMID: 21325794) Int J Mol Sci. 2022 Aug 15;23(16):. (PMID: 36012417) Oncol Rep. 2018 May;39(5):2324-2332. (PMID: 29512748) Urol Oncol. 2015 Feb;33(2):66.e25-31. (PMID: 25037483) Virchows Arch. 2020 Mar;476(3):423-429. (PMID: 31482302) J Oncol. 2018 Aug 6;2018:5167829. (PMID: 30158978) Int J Mol Sci. 2020 Sep 08;21(18):. (PMID: 32911596) Front Oncol. 2019 Aug 07;9:729. (PMID: 31448232) Genes Dev. 2010 Jul 1;24(13):1339-44. (PMID: 20595229) Cell Biosci. 2021 Feb 25;11(1):43. (PMID: 33632341) Eur Urol. 2021 Jan;79(1):82-104. (PMID: 32360052) Sci Rep. 2022 Mar 9;12(1):4141. (PMID: 35264666) Cells. 2020 Jan 23;9(2):. (PMID: 31979244) Cell Death Dis. 2022 Apr 21;13(4):390. (PMID: 35449123) Health Technol Assess. 2010 Jan;14(4):1-331, iii-iv. (PMID: 20082749) Sci Rep. 2022 Nov 22;12(1):20135. (PMID: 36418345) Front Oncol. 2021 May 05;11:668464. (PMID: 34026646) Am J Transl Res. 2022 Jul 15;14(7):4606-4616. (PMID: 35958461) Cancer Biol Ther. 2008 Feb;7(2):255-64. (PMID: 18059191) |
| معلومات مُعتمدة: | Master programs of "Applications of Molecular Biology-Genetics-Diagnostic Biomarkers", "Toxicology" and "Advanced Experimental and Computational Biosciences" University of Thessaly |
| فهرسة مساهمة: | Keywords: ROC analysis; bladder carcinoma; diagnosis and prognosis; genitourinary transcriptomics; miRNAs |
| المشرفين على المادة: | 0 (MicroRNAs) 0 (Biomarkers, Tumor) |
| تواريخ الأحداث: | Date Created: 20231125 Date Completed: 20231127 Latest Revision: 20231127 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10671612 |
| DOI: | 10.3390/ijms242216243 |
| PMID: | 38003433 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!